ES2565190T3 - Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona - Google Patents
Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona Download PDFInfo
- Publication number
- ES2565190T3 ES2565190T3 ES10075728.5T ES10075728T ES2565190T3 ES 2565190 T3 ES2565190 T3 ES 2565190T3 ES 10075728 T ES10075728 T ES 10075728T ES 2565190 T3 ES2565190 T3 ES 2565190T3
- Authority
- ES
- Spain
- Prior art keywords
- reduced
- probability
- pirfenidone
- pirfenidone therapy
- dizziness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title abstract description 17
- 229960003073 pirfenidone Drugs 0.000 title abstract description 17
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 10
- 208000002173 dizziness Diseases 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74197605P | 2005-12-02 | 2005-12-02 | |
| US741976P | 2005-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2565190T3 true ES2565190T3 (es) | 2016-04-01 |
Family
ID=37807840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10075728.5T Active ES2565190T3 (es) | 2005-12-02 | 2006-11-29 | Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona |
| ES06838621T Active ES2385935T3 (es) | 2005-12-02 | 2006-11-29 | Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06838621T Active ES2385935T3 (es) | 2005-12-02 | 2006-11-29 | Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070203202A1 (enExample) |
| EP (2) | EP2316453B1 (enExample) |
| JP (3) | JP5175740B2 (enExample) |
| AT (1) | ATE497766T1 (enExample) |
| CA (1) | CA2631646C (enExample) |
| CY (1) | CY1111355T1 (enExample) |
| DE (1) | DE602006020070D1 (enExample) |
| DK (1) | DK1965797T3 (enExample) |
| ES (2) | ES2565190T3 (enExample) |
| PL (1) | PL1965797T3 (enExample) |
| PT (1) | PT1965797E (enExample) |
| SI (1) | SI1965797T1 (enExample) |
| WO (1) | WO2007064738A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| MX2009006526A (es) * | 2006-12-18 | 2009-06-30 | Intermune Inc | Metodo para suministrar terapia con pirfenidona a un paciente. |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| AP2011005824A0 (en) * | 2009-01-26 | 2011-08-31 | Intermune Inc | Methods for treating acute myocardial infarctions and associated disorders. |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ，インク． | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
| AU2012225611B2 (en) * | 2011-03-08 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Substituted N-Aryl pyridinones |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CA2846824C (en) * | 2011-09-14 | 2021-03-16 | Shionogi & Co., Ltd. | Pharmaceutical composition for inhalation |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| HK1220133A1 (zh) | 2013-03-15 | 2017-04-28 | Intermune, Inc. | 改善微血管完整性的方法 |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
| WO2021107060A1 (ja) * | 2019-11-27 | 2021-06-03 | 塩野義製薬株式会社 | ピルフェニドンの副作用を軽減するための医薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3839346A (en) * | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| DE60234812D1 (de) * | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| WO2004110245A2 (en) * | 2003-05-16 | 2004-12-23 | Intermune, Inc. | Combination therapy for cancer treatment |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
-
2006
- 2006-11-28 US US11/605,199 patent/US20070203202A1/en not_active Abandoned
- 2006-11-29 JP JP2008543435A patent/JP5175740B2/ja active Active
- 2006-11-29 DE DE602006020070T patent/DE602006020070D1/de active Active
- 2006-11-29 DK DK06838621.8T patent/DK1965797T3/da active
- 2006-11-29 EP EP10075728.5A patent/EP2316453B1/en not_active Revoked
- 2006-11-29 ES ES10075728.5T patent/ES2565190T3/es active Active
- 2006-11-29 WO PCT/US2006/045750 patent/WO2007064738A1/en not_active Ceased
- 2006-11-29 PT PT06838621T patent/PT1965797E/pt unknown
- 2006-11-29 PL PL06838621T patent/PL1965797T3/pl unknown
- 2006-11-29 AT AT06838621T patent/ATE497766T1/de active
- 2006-11-29 EP EP06838621A patent/EP1965797B1/en active Active
- 2006-11-29 CA CA2631646A patent/CA2631646C/en active Active
- 2006-11-29 ES ES06838621T patent/ES2385935T3/es active Active
- 2006-11-29 SI SI200630927T patent/SI1965797T1/sl unknown
-
2011
- 2011-03-21 CY CY20111100306T patent/CY1111355T1/el unknown
-
2012
- 2012-08-28 JP JP2012187515A patent/JP2012229275A/ja not_active Withdrawn
-
2015
- 2015-01-08 JP JP2015002231A patent/JP2015061888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5175740B2 (ja) | 2013-04-03 |
| JP2015061888A (ja) | 2015-04-02 |
| DK1965797T3 (da) | 2011-05-02 |
| JP2012229275A (ja) | 2012-11-22 |
| WO2007064738A1 (en) | 2007-06-07 |
| EP1965797A1 (en) | 2008-09-10 |
| EP2316453B1 (en) | 2016-01-06 |
| PL1965797T3 (pl) | 2011-07-29 |
| HK1151726A1 (en) | 2012-02-10 |
| DE602006020070D1 (de) | 2011-03-24 |
| EP1965797B1 (en) | 2011-02-09 |
| ATE497766T1 (de) | 2011-02-15 |
| HK1123213A1 (en) | 2009-06-12 |
| ES2385935T3 (es) | 2012-08-03 |
| EP2316453A1 (en) | 2011-05-04 |
| SI1965797T1 (sl) | 2011-03-31 |
| JP2009518293A (ja) | 2009-05-07 |
| US20070203202A1 (en) | 2007-08-30 |
| CA2631646A1 (en) | 2007-06-07 |
| CA2631646C (en) | 2016-07-26 |
| CY1111355T1 (el) | 2015-08-05 |
| PT1965797E (pt) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2565190T3 (es) | Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona | |
| RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| Calzavara-Pinton et al. | A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications | |
| JP7670700B2 (ja) | 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物 | |
| ES2450615T3 (es) | Composiciones que comprenden Tramadol y Celecoxib para el tratamiento del dolor | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| JP2005529896A5 (enExample) | ||
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| AR053680A1 (es) | Composicion | |
| DOP2006000192A (es) | Formulaciones de ibandronato mejoradas | |
| ES2617252T3 (es) | Solución oral que comprende clorhidrato de atomoxetina | |
| ES2846003T3 (es) | Procedimientos para tratar afecciones pruriginosas mediadas por receptores de histamina H-4 | |
| ES2648225T3 (es) | Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2 | |
| BRPI0510449A (pt) | uso de formulações de meloxicam em medicina veterinária | |
| BRPI0517719A (pt) | composição veterinária transmucosal compreendendo detomidina | |
| ES2950492T3 (es) | Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas | |
| JP2018530612A5 (enExample) | ||
| ES2635421T3 (es) | Composiciones farmacéuticas que comprenden (S)-(+)-7-(1H-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para tratar enfermedades y trastornos cutáneos | |
| ES2688577T3 (es) | Composiciones de buprenorfina en dosis altas y uso como analgésico | |
| AU2024201396A1 (en) | Compositions and methods for the treatment of skin lesions | |
| NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
| Carter | Benefits of Medicating Patients for Veterinary Visits | |
| ES2698403T3 (es) | Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación | |
| Campos et al. | Evaluation of the local analgesic effects of a commercial aqueous extract of Sarracenia purpurea and ammonium sulfate in the equine abaxial sesamoid block model | |
| ES2339265T3 (es) | Uso de acetil l-carnitina en combinacion con propionil l-carnitina y sildenafil para el tratamiento de la difuncion erectil. |